Smartest Doc
The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome
Contraception, 08/20/2012
Clinical Article
Vieira CS et al. – The addition of spironolactone to an oral contraceptives (OCs) containing chlormadinone acetate and ethinylestradiol conferred no cardiovascular risk–marker advantages in young women with polycystic ovary syndrome (PCOS).
Methods- This was a randomized, controlled clinical trial.
- Fifty women with PCOS between 18 and 35 years of age were randomized by a computer program to use OC or OC+SPL.
- Brachial artery flow–mediated vasodilation, carotid intima–media thickness and the carotid artery stiffness index were evaluated at baseline and after 6 and 12 months.
- Serum markers for cardiovascular disease were also analyzed.
- The intragroup data were analyzed using analysis of variance with Tukey's post hoc test.
- A multivariate linear regression model was used to analyze the intergroup data.
- At 12 months, the increase in mean total cholesterol levels was greater in the OC+SPL group than in the OC group (27% vs. 13%, respectively; p=.02).
- The increase in mean sex hormone–binding globulin levels was greater in the OC group than in the OC+SPL group (424% vs. 364%, respectively; p=.01).
- No statistically significant differences between the groups were found for any of the other variables.